Cargando…

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study

BACKGROUND: Identifying predictive biomarkers of drug response is of key importance to improve therapy management and drug selection in cancer therapy. To date, the influence of drug exposure and pharmacogenetic variants on sorafenib-induced toxicity remains poorly documented. The aim of this pharma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boudou-Rouquette, Pascaline, Narjoz, Céline, Golmard, Jean Louis, Thomas-Schoemann, Audrey, Mir, Olivier, Taieb, Fabrice, Durand, Jean-Philippe, Coriat, Romain, Dauphin, Alain, Vidal, Michel, Tod, Michel, Loriot, Marie-Anne, Goldwasser, François, Blanchet, Benoit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418266/ https://www.ncbi.nlm.nih.gov/pubmed/22912756 http://dx.doi.org/10.1371/journal.pone.0042875

Ejemplares similares

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012)

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Noé, Gaëlle, et al.
Publicado: (2019)

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
por: Pécuchet, N, et al.
Publicado: (2012)

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
por: Minot-This, Marie-Sophie, et al.
Publicado: (2022)

Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
por: Coriat, Romain, et al.
Publicado: (2011)

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
por: Tiako Meyo, Manuela, et al.
Publicado: (2020)

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib
por: Noé, Gaёlle, et al.
Publicado: (2016)

First referral to an integrated onco-palliative care program: a retrospective analysis of its timing
por: Barth, Claire, et al.
Publicado: (2020)

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023)

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency
por: Pallet, Nicolas, et al.
Publicado: (2020)

Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study
por: Jouinot, Anne, et al.
Publicado: (2018)

Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2021)

Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options
por: Tlemsani, Camille, et al.
Publicado: (2023)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
por: Huillard, O, et al.
Publicado: (2013)

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
por: Rodier, Thomas, et al.
Publicado: (2022)

Management of arterial bleeding after endoscopic resection of a neuroendocrine gastric tumor
por: Haas, Manon, et al.
Publicado: (2019)

Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study
por: Coriat, Romain, et al.
Publicado: (2016)

Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma
por: Bricaire, Léopoldine, et al.
Publicado: (2017)

Plasma lipidomic analysis to investigate putative biomarkers of P‐glycoprotein activity in healthy volunteers
por: Decaix, Théodore, et al.
Publicado: (2023)

Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitions—ELCAPA Cohort
por: Martinez-Tapia, Claudia, et al.
Publicado: (2022)

Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib
por: Houessinon, Aline, et al.
Publicado: (2016)

Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers
por: Richer, Wilfrid, et al.
Publicado: (2017)

Endoscopic ultrasound efficacy in staging gastric linitis plastica lesion: a retrospective multicentric French study
por: Morgant, Stephanie, et al.
Publicado: (2021)

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
por: Damotte, Diane, et al.
Publicado: (2019)

Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment
por: Couderc, Anne-Laure, et al.
Publicado: (2023)

Computed tomography scan efficacy in staging gastric linitis plastica lesion: a retrospective multicentric French study
por: Morgant, Stéphanie, et al.
Publicado: (2018)

Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19
por: Philippe, Aurélien, et al.
Publicado: (2022)

McCune Albright syndrome is a genetic predisposition to intraductal papillary and mucinous neoplasms of the pancreas associated pancreatic cancer in relation with GNAS somatic mutation – a case report
por: Gaujoux, Sébastien, et al.
Publicado: (2019)

Dispersal syndromes and the use of life-histories to predict dispersal
por: Stevens, Virginie M, et al.
Publicado: (2013)

A new strategy to target regulatory T cells in solid tumors
por: Thomas-Schoemann, Audrey, et al.
Publicado: (2013)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
por: Huh, Ki-Young, et al.
Publicado: (2021)

Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2018)

Author Correction: Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2018)

Diagnostic Yield of Repeat Endoscopic Ultrasound-Guided Fine Needle Biopsy for Solid Pancreatic Lesions
por: Camus, Baptiste, et al.
Publicado: (2023)

Better Management for Neuroendocrine Neoplasms: A Complex Task Ahead
por: Coriat, Romain
Publicado: (2021)

A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis
por: González Serrano, Adolfo, et al.
Publicado: (2023)

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
por: Subbiah, Vivek, et al.
Publicado: (2022)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_948e7jb5l8lf29o1n8nq8hrpmc